Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C

Nicola Coppola,* Ivan Gentile,** Giuseppe Pasquale,* Antonio Riccardo Buonomo,** Nicolina Capoluongo,* Maria D’Armiento,*** Guglielmo Borgia,** Evangelista Sagnelli*

* Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy.
** Department of Clinical Medicine and Surgery, University of Naples Federico II, via S. Pansini, Naples, Italy.
*** Department of Advanced Biomedical Science, University of Naples Federico II, via S. Pansini, Naples, Italy.

INTRODUCTION

The hepatitis C virus (HCV) infects over 170 million people worldwide and is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). After the acute infection about 60-80% of patients develop chronic hepatitis. Roughly one quarter of these patients will develop liver cirrhosis within 20-30 years. The rate of progression of chronic hepatitis C (CHC) is, however, highly variable among patients and over time: some individuals show a benign clinical course for decades and others rapidly progress to end-stage liver disease. Several factors have been linked to the severity of CHC, including virus-related factors (genotype, viral load, duration of infection), co-morbidities (human immunodeficiency virus coinfection, hepatitis B virus coinfection, insulin-resistance, high body mass index, immunosuppression), and iron overload. Host-related factors, such as age at the onset of infection and gender, and lifestyle factors (alcohol intake) have also been implicated in the severity of CHC. It has been demonstrated that eradication of infection with antiviral therapy is associated with a reduced progression to cirrhosis and even with its regression.

The development of sensitive assays to detect small amounts of HBV DNA has favored the identification of occult hepatitis B infection, which is characterized by undetectable HBsAg in serum and HBV DNA detectable in the liver tissue. In patients with chronic hepatitis C, occult HBV infection...
was found to be associated with more severe liver damage,\textsuperscript{12,13} a higher risk of developing HCC\textsuperscript{14-19} and HBV reactivation in immunosuppressed patients,\textsuperscript{20,21} such as onco-hematological patients receiving chemotherapy.\textsuperscript{22} This virological condition has been more frequently found in patients with serological markers of previous HBV infection (anti-HBc, anti-HBs) than in those without.\textsuperscript{23} However, it is still debated whether the presence of anti-HBc in patients with HCV-related hepatitis is linked to a greater risk of severe hepatitis and HCC.\textsuperscript{24}

**OBJECTIVES**

The aim of our study was to evaluate whether the presence of anti-HBc antibodies and, therefore, previous contact with the hepatitis B virus, was associated with cirrhosis in a group of patients with biopsy-proven HCV-related chronic hepatitis.

**MATERIAL AND METHODS**

**Patients**

We reviewed the charts of all patients with chronic hepatitis C admitted for a liver biopsy to the Department of Mental Health and Public Medicine, Section of Infectious Diseases (Second University of Naples), and to the Department of Public Medicine and Social Security-Section of Infectious Diseases (University of Naples “Federico II”, Italy) from 01.01.2000 to 30.06.2012. These two centers have cooperated in several clinical investigations using the same clinical approach and the same laboratory methods.\textsuperscript{25}

Inclusion criteria:

- Positivity for anti-HCV.
- HCV RNA in serum and the availability of liver biopsy data.

Exclusion criteria:

- HBsAg and/or anti-HIV positivity.
- Incomplete liver panel (including test for the anti-HBc antibody).
- Hepatocellular carcinoma, ascites, liver transplantation, insufficient liver tissue for staging.

Two hundred and twenty-two consecutive Italian patients with anti-HCV/HCV RNA-positive chronic hepatitis for 18-36 months were included in the study. Patients underwent complete physical examination, full liver function tests, blood cell counts, viral marker tests (HBV, HCV, hepatitis delta virus-HDV, human immunodeficiency virus-HIV) and liver ultrasound scan.

The laboratory tests were performed within 1 month of the date of the liver biopsy. Alcohol consumption was defined as drinking more than 30 g per day of alcohol for at least 6 months. This was corroborated by the patient’s family.

Liver biopsy was performed for all patients with an 18-gauge needle under ultrasound guidance. Liver specimens were fixed in formalin, embedded in paraffin and stained with hematoxylin-eosin and Masson’s trichrome stain. In each case, the liver specimens were more than 2 cm in length and had more than 11 portal tracts. Liver biopsies were examined by a pathologist (G.P.) who, unaware of the clinical and laboratory data, used the Ishak scoring system to grade necroinflammation and fibrosis.\textsuperscript{26} Patients with fibrosis score 5 or 6 were considered as having histological cirrhosis.

All procedures used were in accordance with the international guidelines and with the Helsinki Declaration of 1975 and revised in 1983.

**Routine analysis**

HBV and HDV serum markers were sought using commercial immunoenzymatic assays (Abbott Laboratories, North Chicago, IL, USA, for HBsAg, anti-HBs and anti-HBc, and DiaSorin, Saluggia, VC, Italy, for anti-HDV). The anti-HCV antibody was sought using a 3rd generation commercial immunoenzymatic assay (Ortho Diagnostic Systems, Neckargemund, Germany). Antibodies to HIV 1 and 2 were sought using a commercial ELISA (Abbott Lab., North Chicago, Ill, USA). Liver function tests were performed by the routine methods.

**HCV genotype and viral load**

The HCV genotype was determined using the HCV genotype assay Lipa (Bayer, France), following the manufacturer’s instructions. Viral RNA was extracted from 140-µL samples of plasma using a microspin column (QIAamp RNA viral kit, Qiagen GmbH, Hilden, Germany). HCV RNA was quantified by performing a real-time polymerase chain reaction (PCR) in a Light cycler 1.5 (Roche Diagnostics, Branchburg, NJ, USA), as previously described;\textsuperscript{27} by this method, the detection limit in plasma samples is estimated at around 40 IU/mL.
Statistical analysis

The Kolmogorov-Smirnov test was used to assess the distribution of the quantitative variables. These variables are reported as mean ± standard deviation (SD), while in the case of a non-Gaussian distribution they are reported as median and interquartile range (IQR). For comparisons, for the Gaussian distribution, the Student t-test for unpaired variables was applied, while the Mann-Whitney U test was used for a non-Gaussian distribution or for quantitative ordinal variables. The χ² test with the Yates correction (or Fisher’s exact test where appropriate) was used for qualitative variables. The correlation between quantitative ordinal variables was assessed with the Spearman ρ test. P < 0.05 in a two-sided test was considered statistically significant. Any independent variable (or with P ≤ 0.2 at univariate analysis) with a biological plausibility to the aim of the study was included in the binary logistic regression analysis using the forward conditional stepwise method. The cut-off values used for the stepwise method were: P = 0.05 for entry to the model, and P = 0.10 for removal. All statistical analyses were carried out using the Statistical Package for the Social Sciences, version 18.0 (SPSS Inc. Chicago, Ill).

RESULTS

The demographic, biochemical, serological, virological and histological data obtained at the time of the diagnostic liver biopsy are shown in table 1. The patients were relatively young (median and range: 47 years, 35.75-56) and prevalently (58.6%) males. Thirty-three (14.9%) admitted alcohol consumption and 19 (8.6%) had been previously treated with interferon (Table 1). HCV genotype 1 prevailed (52.3% of cases), the median HCV RNA in serum was 800,000 IU/mL (range 276,000-3,405,000) and 77 patients (34.7%) showed anti-HBc in serum (Table 1). The presence of anti-HBc was associated with histological cirrhosis, as it was identified in 21 (63.6%) of the 33 patients with a fibrosis score 5 or 6 and in 56 (29.6%; p < 0.001) of the 189 with a score ≤ 4 (Table 2). A significant correlation was found between the grading and staging scores (ρ = 0.498; p < 0.001). In addition, patients with cirrhosis had a significantly higher grading than those without cirrhosis (median = 8, IQR 6-11 in patients with cirrhosis vs. median = 6, IQR = 4-8 in patients without cirrhosis, p < 0.001). However, the patients with anti-HBc antibodies had a similar grading to those without (median = 4, IQR 4-8 vs. median = 7, IQR = 4-8, respectively, p < 0.138).

To confirm the association between positivity for anti-HBc and histological cirrhosis, a multivariate logistic regression analysis was done. The analysis included the presence of anti-HBc and other potential confounding factors (age and sex). After all the other factors were taken into account, anti-HBc p < 0.001), had a higher mean serum value of AST (87 [61.5-117] vs. 51 [36-80.5] IU/mL, p < 0.001), ALT (120 [72-188] vs. 56 [40-116] IU/mL, p < 0.001), a lower platelet count (136,000 [116,000-159,600] vs. 213,000 [180,500-255,500] cells/mL, p < 0.001) and prothrombin activity (91% [85.5-100] vs. 99 [91.5-106], p < 0.001) (Table 2).

Table 1. Demographic and clinical characteristics of the patients (n = 222).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>47 (35.75-56)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>58.6%</td>
</tr>
<tr>
<td>F</td>
<td>41.4%</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>14.9%</td>
</tr>
<tr>
<td>Previous interferon treatment</td>
<td>8.6%</td>
</tr>
<tr>
<td>HCV genotype (n = 181)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>52.3%</td>
</tr>
<tr>
<td>2</td>
<td>17.1%</td>
</tr>
<tr>
<td>3</td>
<td>10.4%</td>
</tr>
<tr>
<td>4</td>
<td>1.4%</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>56 (39.75-88)</td>
</tr>
<tr>
<td>ALT (IU/L)</td>
<td>64 (42.75-125.25)</td>
</tr>
<tr>
<td>Platelets (elements/µL)</td>
<td>203,050 (161,750-246,750)</td>
</tr>
<tr>
<td>Prothrombin activity (%)</td>
<td>97% (90-105)</td>
</tr>
<tr>
<td>HCV RNA (IU/mL)</td>
<td>800,000 (276,00-3,405,000)</td>
</tr>
<tr>
<td>Anti-HBc positivity</td>
<td>34.7%</td>
</tr>
<tr>
<td>Grading</td>
<td>6 (4-8)</td>
</tr>
<tr>
<td>Staging</td>
<td>2 (1-4)</td>
</tr>
<tr>
<td>Cirrhosis *</td>
<td>14.9%</td>
</tr>
<tr>
<td>Steatosis *</td>
<td>50.5%</td>
</tr>
</tbody>
</table>

The data are given as median (interquartile range) for quantitative variables and as a percentage for qualitative variables. * Histologically detected.
positivity, age and sex were independent predictors of histological cirrhosis (Table 3).

Analyzing only the 77 patients who were anti-HBc positive, cirrhosis was detected in 21 (27.3%) cases. Among these 77 subjects, patients with cirrhosis had significantly higher levels of AST (79 IU/L, IQR: 61.5-117 vs. 48 IU/L, IQR: 36-80.5, P < 0.001) and ALT (120 IU/L, IQR: 72-188 vs. 56 IU/L, IQR: 40-116, P < 0.001) and grading (9, IQR: 6.5-100 vs. 99 (91.5-106), P = 0.006 and a lower platelet count (140,000/µL, IQR: 116,500-167,500 vs. 226,000/µL, IQR: 190,500-256,750, P ≤ 0.001) compared to those without cirrhosis. All other variables in this subgroup of patients did not differ significantly in presence or absence of cirrhosis. Particularly age was not-significantly higher in patients with cirrhosis than in those without cirrhosis (52 years, IQR:46-58.5 vs. 50.5 years, IQR 42.25-56, p = 0.227).

**DISCUSSION**

The data from the present study indicated that in the patients with chronic hepatitis C, positivity for anti-HBc was independently associated with severe fibrosis. In fact, of the 33 patients with histological cirrhosis, 63.6% were anti-HBc-positive, a higher percentage than that (29.6%) observed in the 189 patients without cirrhosis. Other factors associated with severe fibrosis were an older age and male sex, as already reported in other studies.\(^5,25,28\) Moreover, a significant correlation was found between the grading and staging scores, even though the grading was similar in the patients with anti-HBc antibodies and in those without. Instead, the steatosis score was not associated with histological cirrhosis.

The presence of anti-HBc in the serum without serological HBsAg is indicative of a resolved HBV infection. However, it may be considered a surrogate
marker of occult HBV infection, as suggested by several authors. In a previous study on 89 HBsAg-negative/anti-HCV-positive patients, the occult HBV infection was detected by a highly sensitive PCR in plasma or peripheral blood mononuclear cells or liver tissue in about 60% and 80% of the anti-HBs-positive/anti-HBe-positive and anti-HBs-negative/anti-HBe-positive patients, respectively, and in only about 10% of those who were negative for both anti-HBs and anti-HBe. However, the absence of demonstration of HBV in liver tissue in this study was a limitation. An indirect demonstration of the role of anti-HBc as a surrogate marker of occult HBV infection was that the reactivation of HBV infection in HBsAg-negative patients with immunosuppression was observed exclusively in the anti-HBc-positive.

Our data comply with the data of some previous studies in which occult HBV infection was described as associated with the more severe stages of the liver disease. For example, in a previous study of ours, the 88 anti-HBc-positive patients with HCV-related chronic infection showed a higher percentage of severe liver disease than the 97 anti-HBe-negative patients (72.7 vs. 46.4%, respectively, P < 0.0005). The mechanism leading to more severe fibrosis in anti-HBc-positive patients with CHC has not been elucidated completely. However, the data in the literature allow us to hypothesize that the hepatocytes with a low-level occult HBV replication may be a suitable target for cytotoxic T cells previously sensitized to viral antigens. As regards the entity of the immune reaction, it should be remembered that in chronic hepatitis B the cytotoxic T cell-mediated attack is frequently strong in cases with a low to moderate exposure of the viral antigens on the membrane of the hepatocytes and weak in cases with a high expression. The persistence of low-level HBV replication in the hepatocytes and the consequent immunoreactions may bring about increased severity of the liver disease and more marked fibrosis. However, it is not possible to rule out that the anti-HCV-positive/HBsAg-negative, but anti-HBc-positive patients may be at the last step in a hypothetical sequence of events leading to a progressive suppression of HBV replication during HBV-HCV chronic coinfection, as suggested by Tanaka, et al. In fact, HCV or HBV chronic carriers who became super-infected with HBV or HCV, respectively, experienced a strong inhibition of the pre-existing viral genome, but a severe liver disease. Thus, an accumulative effect of HBV and HCV infection was hypothesized for these patients. This hypothesis seems to be confirmed by the data from this study showing a similar grading in anti-HBc-positive and -negative patients; thus, we might hypothesize that histological cirrhosis was more frequent in our anti-HBc-positive patients because of an accumulative effect of HBV and HCV infection, as in chronic dual coinfection.

CONCLUSION

Our data indicating that the anti-HBc-positive patients had a high prevalence of severe liver disease further support the idea that anti-HBc positivity is a marker of clinical value in patients with chronic hepatitis C.

ABBREVIATIONS

- CHC: chronic hepatitis C.
- HBV: hepatitis B virus.
- HCC: hepatocellular carcinoma.
- HCV: hepatitis C virus.
- HDV: hepatitis D virus.
- HIV: human immunodeficiency virus.

REFERENCES

